Metformin, a first-line antidiabetic drug, significantly increases proliferative FGSCs and upregulates PCNA, cyclin D2, p-mTOR, and p-AMPK in PCOS mice, restoring FGSCs function via AMPK/mTOR signaling (Wang et al. 2022). Here, MTOR is linked to polycystic ovary syndrome.